Section Arrow
SYRE.NASDAQ
- Spyre Therapeutics
Quotes are at least 15-min delayed:2025/07/21 08:34 EDT
Pre Market
Last
 16.29
0 (0.00%)
Bid
16.32
Ask
26.11
High 16.29 
Low 16.29 
Volume
Regular Hours
Last
 16.29
-0.6 (-3.55%)
Day High 
17.185 
Prev. Close
16.89 
1-M High
17.29 
Volume 
333.17K 
Bid
16.32
Ask
26.11
Day Low
16.08 
Open
17.11 
1-M Low
14 
Market Cap 
1.02B 
Currency USD 
P/E 2.68 
%Yield -- 
10-SMA 15.97 
20-SMA 15.64 
50-SMA 15.57 
52-W High 40.26 
52-W Low 10.91 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.06/-4.70
Enterprise Value
1.02B
Balance Sheet
Book Value Per Share
5.41
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 2.02 -0.26 -11.40%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 12.67 -1.405 -9.98%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0561 +0.0084 +17.61%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.17 +0.33 +5.65%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.2985 +0.3785 +6.39%
Quotes are at least 15-min delayed:2025/07/21 08:34 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.